全文获取类型
| 收费全文 | 16298篇 |
| 免费 | 1044篇 |
| 国内免费 | 77篇 |
专业分类
| 耳鼻咽喉 | 128篇 |
| 儿科学 | 424篇 |
| 妇产科学 | 412篇 |
| 基础医学 | 2608篇 |
| 口腔科学 | 660篇 |
| 临床医学 | 1348篇 |
| 内科学 | 3576篇 |
| 皮肤病学 | 341篇 |
| 神经病学 | 1950篇 |
| 特种医学 | 447篇 |
| 外科学 | 1448篇 |
| 综合类 | 41篇 |
| 一般理论 | 5篇 |
| 预防医学 | 973篇 |
| 眼科学 | 271篇 |
| 药学 | 1343篇 |
| 中国医学 | 57篇 |
| 肿瘤学 | 1387篇 |
出版年
| 2024年 | 12篇 |
| 2023年 | 151篇 |
| 2022年 | 196篇 |
| 2021年 | 588篇 |
| 2020年 | 360篇 |
| 2019年 | 477篇 |
| 2018年 | 574篇 |
| 2017年 | 451篇 |
| 2016年 | 522篇 |
| 2015年 | 649篇 |
| 2014年 | 738篇 |
| 2013年 | 936篇 |
| 2012年 | 1469篇 |
| 2011年 | 1563篇 |
| 2010年 | 775篇 |
| 2009年 | 741篇 |
| 2008年 | 1166篇 |
| 2007年 | 1089篇 |
| 2006年 | 1015篇 |
| 2005年 | 925篇 |
| 2004年 | 829篇 |
| 2003年 | 754篇 |
| 2002年 | 641篇 |
| 2001年 | 75篇 |
| 2000年 | 54篇 |
| 1999年 | 69篇 |
| 1998年 | 105篇 |
| 1997年 | 94篇 |
| 1996年 | 60篇 |
| 1995年 | 57篇 |
| 1994年 | 42篇 |
| 1993年 | 30篇 |
| 1992年 | 19篇 |
| 1991年 | 16篇 |
| 1990年 | 12篇 |
| 1989年 | 23篇 |
| 1988年 | 15篇 |
| 1987年 | 22篇 |
| 1986年 | 14篇 |
| 1985年 | 14篇 |
| 1984年 | 11篇 |
| 1983年 | 14篇 |
| 1982年 | 13篇 |
| 1981年 | 12篇 |
| 1980年 | 5篇 |
| 1979年 | 5篇 |
| 1978年 | 4篇 |
| 1975年 | 3篇 |
| 1973年 | 6篇 |
| 1961年 | 1篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
1.
Thomas Felix John B. Jordan Catherine Akers Bina Patel Daniela Drago 《Expert opinion on drug safety》2019,18(3):231-240
Introduction: Pharmacovigilance is essential to monitoring the safety profiles of authorized medicines. Compared with small-molecule drugs, biological drugs are more complex, more susceptible to structural variability due to manufacturing processes, and have the potential to induce immune-related reactions, underscoring the importance of safety monitoring for these products. Although highly similar to reference products, biosimilars are not expected to be structurally identical. For these reasons, proper reporting of potential adverse drug reactions (ADRs) using distinguishable names and batch numbers is essential for accurate tracing of all biological drugs. To address the need for robust pharmacovigilance, the European Parliament and Council of the European Union provided legislation regarding pharmacovigilance of biologics in 2010.
Areas covered: This narrative review examines the current state of pharmacovigilance for biologics in the European Union (EU) and discusses relevant information on pharmacovigilance of biosimilars, the current EU pharmacovigilance system, and areas that could be improved.
Expert opinion: Although steps have been taken to improve pharmacovigilance of biologics in the EU, several enhancements can still be made, including additional training for healthcare professionals on ADR reporting, the use of 2D barcodes that enhance traceability, and an open discussion of potentially missed opportunities in the pharmacovigilance of biosimilars. 相似文献
2.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献3.
Iacopo Chiodini Daniela Merlotti Alberto Falchetti 《Expert opinion on pharmacotherapy》2020,21(6):721-732
ABSTRACT
Introduction
Glucocorticoid (GC) induced osteoporosis (GIOP) is the most common form of secondary osteoporosis. It develops in a dose and time dependent manner, due to a rapid and transient increase in bone resorption, followed by the inhibition of bone formation. 相似文献4.
5.
6.
7.
8.
9.
10.